About this trial

The primary endpoint is the assessment of the clinical value of a novel high-resolution mobile PET-CT scanner for intraoperative margin assessment in oral squamous cell carcinoma, soft tissue sarcoma and osteosarcoma surgery. The predicted margin status will be correlated with the margin status determined with histopathology.

Eligibility criteria

Qualifiers

Age ≥18 years.

Patient is confirmed with oral squamous cell carcinoma, soft tissue sarcoma or osteosarcoma.

Patient is indicated to undergo curative surgery of the primary tumor.

Patient is estimated compliant for study participation by the investigator.

Disqualifiers

Medical or psychiatric conditions that compromise the patient's ability to give informed consent;

Patient has previously received radiotherapy of the primary tumor region;

Patient has participated in other clinical studies with radiation exposure of more than 1 mSv in the past 12 months;

A blood glucose level over 200 mg/dL on the day of surgery.

Trial design

Treatments tested in this trial

  • XEOS AURA 10

Treatment groups

30 Participants
are divided into 1 treatment group

Locations

1
University Medical Center Groningen9713 GZ, Groningen Netherlands

Sponsors and collaborators

University Medical Center Groningen

Lead sponsor